



**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula (IE) or a salt, N-oxide, hydrate or solvate thereof, for use in human or veterinary medicine:




wherein R<sub>1</sub> has the formula (IIA):



wherein R represents bromo, chloro, phenyl, C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl(C<sub>1</sub>-C<sub>6</sub> alkyl)

~~R<sub>1</sub> is a group of formula (II):~~



~~wherein in any compatible combination~~

~~Alk<sup>1</sup> and Alk<sup>2</sup> are optionally substituted divalent C<sub>1</sub>-C<sub>6</sub> alkylene or C<sub>2</sub>-C<sub>6</sub> alkenylene radicals,~~

~~p, r and s are independently 0 or 1,~~

~~Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO<sub>2</sub>-, -C(=O)O-, -C(=O)NR<sup>A</sup>-, -C(=S)NR<sup>A</sup>-, -SO<sub>2</sub>NR<sup>A</sup>-, -NR<sup>A</sup>C(=O)-, -NR<sup>A</sup>SO<sub>2</sub>- or -NR<sup>A</sup>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,~~

~~Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical, and~~

~~R represents hydrogen or one or more substituents selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COOR<sup>A</sup>-, -COR<sup>A</sup>-, -SO<sub>2</sub>R<sup>A</sup>-, -CONH<sub>2</sub>-, -SO<sub>2</sub>NH<sub>2</sub>-, -CONHR<sup>A</sup>-, -SO<sub>2</sub>NHR<sup>A</sup>-, -CONR<sup>A</sup>R<sup>B</sup>-, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>-, -NH<sub>2</sub>-, -NHR<sup>A</sup>-, -NR<sup>A</sup>R<sup>B</sup>-, -OCONH<sub>2</sub>-, -OCONHR<sup>A</sup>-, -OCONR<sup>A</sup>R<sup>B</sup>-, -NHCOR<sup>A</sup>-, -NHCOOR<sup>A</sup>-, -NR<sup>B</sup>COOR<sup>A</sup>-, -NH<sub>2</sub>SO<sub>2</sub>OR<sup>A</sup>-, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>-, -NHCONH<sub>2</sub>-, -NR<sup>A</sup>CONH<sub>2</sub>-, -NHCONHR<sup>B</sup>-, -NR<sup>A</sup>CONHR<sup>B</sup>-, -NHCONR<sup>A</sup>R<sup>B</sup>- or -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup>- wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl group.~~

R<sub>2</sub> is hydrogen or

(i) a group of formula (IA) as defined in relation to R<sub>4</sub>;

(ii) a carboxamide radical; or

(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk<sup>1</sup>)<sub>p</sub>-(Z)<sub>r</sub>(Alk<sup>2</sup>)<sub>s</sub>-Q wherein Q, Alk<sup>1</sup>, Alk<sup>2</sup>, Z, p, r and s are as defined above in relation to group (IA); in any compatible combination

Alk<sup>1</sup> and Alk<sup>2</sup> are divalent C<sub>1</sub>-C<sub>6</sub> alkylene or C<sub>2</sub>-C<sub>6</sub> alkenylene radicals,

p, r and s are independently 0 or 1,

Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO<sub>2</sub>-, -C(=O)O-, -C(=O)NR<sup>A</sup>-, -C(=S)NR<sup>A</sup>-, -SO<sub>2</sub>NR<sup>A</sup>-, -NR<sup>A</sup>C(=O)-, -NR<sup>A</sup>SO<sub>2</sub>- or -NR<sup>A</sup>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and

Q is hydrogen or a carbocyclic or heterocyclic radical;

wherein each of Alk<sup>1</sup>, Alk<sup>2</sup>, and Q are optionally substituted with one or more substituents selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COOR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>, -CONHR<sup>A</sup>, -SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOR<sup>A</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NHSO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, -NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONHR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, or --NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup>, wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl group; and

R<sub>3</sub> is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, or C<sub>2</sub>-C<sub>6</sub>alkynyl; or a carboxyl, carboxamide or carboxyl ester group,

PROVIDED THAT at least one of R<sub>2</sub> and R<sub>3</sub> is present and is other than hydrogen.

Claims 2-14 (Canceled)

15. (Previously Presented) The compound as claimed in claim 1 wherein R<sub>2</sub> is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.

16. (Previously Presented) The compound as claimed in claim 1 wherein R<sub>2</sub> is optionally substituted phenyl.

17. (Withdrawn) The compound as claimed in claim 1 wherein R<sub>2</sub> is a carboxamide radical of formula -CONR<sup>B</sup>(Alk)<sub>n</sub>R<sup>A</sup> wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

$R^B$  is hydrogen or a  $C_1$ - $C_6$  alkyl or  $C_2$ - $C_6$  alkenyl group,

$R^A$  is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

18. (Withdrawn – Currently Amended) The compound as claimed in claim 17 wherein

Alk is an optionally substituted  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $CH_2CH=CH-$ , or  $-CH_2CCCH_2-$  radical.

n is 0 or 1 ,

$R^B$  is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

$R^A$  is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl,

or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

19. (Withdrawn) The compound as claimed in claim 17 wherein n is 0,  $R^B$  is hydrogen and  $R^A$  is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.
20. (Withdrawn) The compound as claimed in claim 1 wherein  $R_3$  is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.

21. (Withdrawn) The compound as claimed in claim 1 wherein  $R_3$  is a carboxamide group  $-\text{CONR}^B(\text{Alk})_n\text{R}^A$  wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

$R^B$  is hydrogen or a  $C_1$ - $C_6$  alkyl or  $C_2$ - $C_6$  alkenyl group,

$R^A$  is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or  $R^A$  and  $R^B$  taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

22. (Withdrawn) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (IE) as defined in claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.

23. (Withdrawn) The method as claimed claim 22 for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.

24. (Canceled)

25. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as defined in claim 1, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.